Cargando…
Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance
Several clinical trials started during the COVID-19 pandemic to discover effective therapeutics led to identify a few candidates from the major clinical trials. However, in the past several months, quite a few SARS-CoV-2 variants have emerged with significant mutations. Major mutations in the S-glyc...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606259/ https://www.ncbi.nlm.nih.gov/pubmed/34920267 http://dx.doi.org/10.1016/j.coph.2021.11.006 |
_version_ | 1784602307375136768 |
---|---|
author | Chakraborty, Chiranjib Bhattacharya, Manojit Sharma, Ashish Ranjan |
author_facet | Chakraborty, Chiranjib Bhattacharya, Manojit Sharma, Ashish Ranjan |
author_sort | Chakraborty, Chiranjib |
collection | PubMed |
description | Several clinical trials started during the COVID-19 pandemic to discover effective therapeutics led to identify a few candidates from the major clinical trials. However, in the past several months, quite a few SARS-CoV-2 variants have emerged with significant mutations. Major mutations in the S-glycoprotein and other parts of the genome have led to the antibody's escape to small molecule-based therapeutic resistance. The mutations in S-glycoprotein trigger the antibody escape/resistance, and mutations in RdRp might cause remdesivir resistance. The article illustrates emerging mutations that have resulted in antibody escape to therapeutics resistance. In this direction, the article illustrates presently developed neutralizing antibodies (with their preclinical, clinical stages) and antibody escapes and associated mutations. Finally, owing to the RdRp mutations, the antiviral small molecules resistance is illustrated. |
format | Online Article Text |
id | pubmed-8606259 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86062592021-11-22 Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance Chakraborty, Chiranjib Bhattacharya, Manojit Sharma, Ashish Ranjan Curr Opin Pharmacol Article Several clinical trials started during the COVID-19 pandemic to discover effective therapeutics led to identify a few candidates from the major clinical trials. However, in the past several months, quite a few SARS-CoV-2 variants have emerged with significant mutations. Major mutations in the S-glycoprotein and other parts of the genome have led to the antibody's escape to small molecule-based therapeutic resistance. The mutations in S-glycoprotein trigger the antibody escape/resistance, and mutations in RdRp might cause remdesivir resistance. The article illustrates emerging mutations that have resulted in antibody escape to therapeutics resistance. In this direction, the article illustrates presently developed neutralizing antibodies (with their preclinical, clinical stages) and antibody escapes and associated mutations. Finally, owing to the RdRp mutations, the antiviral small molecules resistance is illustrated. Elsevier Ltd. 2022-02 2021-11-22 /pmc/articles/PMC8606259/ /pubmed/34920267 http://dx.doi.org/10.1016/j.coph.2021.11.006 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Chakraborty, Chiranjib Bhattacharya, Manojit Sharma, Ashish Ranjan Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance |
title | Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance |
title_full | Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance |
title_fullStr | Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance |
title_full_unstemmed | Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance |
title_short | Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance |
title_sort | emerging mutations in the sars-cov-2 variants and their role in antibody escape to small molecule-based therapeutic resistance |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606259/ https://www.ncbi.nlm.nih.gov/pubmed/34920267 http://dx.doi.org/10.1016/j.coph.2021.11.006 |
work_keys_str_mv | AT chakrabortychiranjib emergingmutationsinthesarscov2variantsandtheirroleinantibodyescapetosmallmoleculebasedtherapeuticresistance AT bhattacharyamanojit emergingmutationsinthesarscov2variantsandtheirroleinantibodyescapetosmallmoleculebasedtherapeuticresistance AT sharmaashishranjan emergingmutationsinthesarscov2variantsandtheirroleinantibodyescapetosmallmoleculebasedtherapeuticresistance |